Floatz logo

VNX-202

HER2 Expressing Solid Tumors

Vironexis Biotherapeutics Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HER2 Expressing Solid Tumors cohort.

Asset / SponsorPhaseRating
Adxs31-164
Advaxis, Inc.
Phase 1/2CCC

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →